Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

NEXT STORY
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
PREV STORY
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

author_avatar
NASDAQ Market News

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

author_avatar
NASDAQ Market News

FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

author_avatar
NASDAQ Market News